Purinergic Signaling in Health and Disease
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 2273
Special Issue Editor
Special Issue Information
Dear Colleagues,
Extracellular adenosine, adenine nucleotides and uracil nucleotides play important roles in the control of the function of cells, organs and organ systems. Adenosine activates four human G-protein-coupled receptors. P2Y receptors are G-protein-coupled receptors for adenine nucleotides and uracil nucleotides. There are eight human subtypes. P2X receptors are ligand-gated receptors for adenine nucleotides with a trimeric protein structure. Seven human P2X subtypes build these trimers. Agonists and antagonists have been developed for use in pharmacotherapy. Adenosine and analogues are used for the diagnosis and therapy of cardiovascular diseases. The adenosine receptor antagonist theophylline can be used for the treatment of bronchial asthma. The subtype-selective A2A-receptor antagonist istradefylline is approved in Japan and the United States for the treatment of Parkinson's disease. The P2Y2 receptor agonist diquafosol is used for the treatment of dry-eye disease. Several P2Y12 receptor antagonists inhibit platelet aggregation in the prevention and therapy of cardiovascular events such as myocardial infarction. The active metabolites of clopidogrel and prasugrel interact with the P2Y12 receptor proteins in an irreversible manner, whereas ticagrelor and cangrelor are reversible antagonists. P2X3 receptor antagonists are in development to reduce the sensitization of nerve fibers, for example, for the treatment of chronic cough.
Prof. Dr. Ivar von Kügelgen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adenosine receptors
- P2Y receptors
- P2X receptors
- Parkinson's disease
- dry eye disease
- platelet aggregation
- cardiovascular diseases
- myocardial infarction
- chronic cough
